https://www.selleckchem.com/pr....oducts/diabzi-sting-
44, 95 CI; 0.22-0.91, p=0.02). While the median overall survival for patients who had received sunitinib was 11.0 months, it has not been reached the median in the pazopanib arm (11.0 months vs NR, p=0.051). Discussion We demonstrated significantly better progression-free survival and a higher objective response rate with nivolumab treatment in patients who had received pazopanib as compared with patients who received sunitinib in the pre-nivolumab period.Spontaneous pneumomediastinum (SPM) is a relatively uncomm
Giống
Bình luận
Đăng lại
